Affiliation:
1. National Organization for Drug Control and Research (NODCAR)
2. Cairo University Faculty of Pharmacy
Abstract
Abstract
An economical & eco-friendly spectrofluorometric technique has been developed for the determination of prucalopride succinate (PRU) in human urine on the basis of drug’s native fluorescence. The type of solvent and the wavelengths of excitation and emission have been carefully selected for optimal experimental conditions. In deionized water, the fluorescence intensity was measured at λ emission 362 nm upon excitation at 310 nm. This bio-validated method was carried out using 30uL urine without carrying out any preliminary steps. The calibration curve for PRU shows a linear relationship in a concentration range of 0.75–5.5µg/mL. The validation of this proposed technique obeys EMA Guidelines for validating bioanalytical methods and the greenness assessment was evaluated according to the Analytical GAPI approach.
Publisher
Research Square Platform LLC
Reference15 articles.
1. Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?;Kaza M;J Pharm Biomed Anal,2019
2. Effect of renal impairment on the pharmacokinetics of prucalopride: a single-dose open-label phase I study;Smith WB;Drug Des Devel Ther,2012
3. Development & Validation of RP-HPLC method for estimation of prucalopride succinate in pharmaceutical dosage form;Vaibhavi N;WORLD J Pharm Pharm Sci,2020
4. Development And Validation Of A Stability Indicating Rp-Hplc Method For The Determination Of Prucalopride Succinate;Kanthale SBTS,2020
5. Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry;Zuo L;J Pharm Biomed Anal,2016